Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.

Por Dørum, A, Heimdal, K, Hovig, E, Inganäs, M, Møller, P
Publicado em 1999

Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation.

Por Hollstein, M, Shomer, B, Greenblatt, M, Soussi, T, Hovig, E, Montesano, R, Harris, C C
Publicado em 1996

Intracellular metabolism of a 2'-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or asfree ribozyme. A study by capillary electrophoresis.

Por Prasmickaite, L, Hogset, A, Maelandsmo, G, Berg, K, Goodchild, J, Perkins, T, Fodstad, O, Hovig, E
Publicado em 1998

Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects.

Por Hainaut, P, Soussi, T, Shomer, B, Hollstein, M, Greenblatt, M, Hovig, E, Harris, C C, Montesano, R
Publicado em 1997

P17.94 GLIOMA GWAS HITS - MARKERS FOR RISK OR FOR PROGNOSIS?

Por Wibom, C., Spaeth, F., Dahlin, A., Langseth, H., Hovig, E., Rajaraman, P., Andersson, U., Melin, B.
Publicado em 2014

Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1.

Por Maelandsmo, G. M., Berner, J. M., Flørenes, V. A., Forus, A., Hovig, E., Fodstad, O., Myklebost, O.
Publicado em 1995

Interferon-γ suppresses S100A4 transcription independently of apoptosis or cell cycle arrest

Por Andersen, K, Smith-Sørensen, B, Pedersen, K B, Hovig, E, Myklebost, O, Fodstad, Ø, Mælandsmo, G M
Publicado em 2003

Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.

Por Maelandsmo, G. M., Flørenes, V. A., Hovig, E., Oyjord, T., Engebraaten, O., Holm, R., Børresen, A. L., Fodstad, O.
Publicado em 1996

Database of p53 gene somatic mutations in human tumors and cell lines.

Por Hollstein, M, Rice, K, Greenblatt, M S, Soussi, T, Fuchs, R, Sørlie, T, Hovig, E, Smith-Sørensen, B, Montesano, R, Harris, C C
Publicado em 1994

One test to identify 50% of all Norwegian BRCA1 mutations

Por Møller, P, Hovig, E, Lycke, K, Stacy, RAP, Dahlberg, OJ, Hagen, A, Hagen, B, Løvslett, K, Qvist, H, Heimdal, K
Publicado em 2000

Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations.

Por Børresen, A L, Hovig, E, Smith-Sørensen, B, Malkin, D, Lystad, S, Andersen, T I, Nesland, J M, Isselbacher, K J, Friend, S H
Publicado em 1991

BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study

Por Bjørge, T, Lie, A K, Hovig, E, Gislefoss, R E, Hansen, S, Jellum, E, Langseth, H, Nustad, K, Tropé, C G, Dørum, A
Publicado em 2004

High number of kinome‐mutations in non‐small cell lung cancer is associated with reduced immune response and poor relapse‐free survival

Por Helland, Å., Brustugun, O. T., Nakken, S., Halvorsen, A. R., Dønnem, T., Bremnes, R., Busund, L. T., Sun, J., Lorenz, S., Solberg, S. K., Jørgensen, L. H., Vodak, D., Myklebost, O., Hovig, E., Meza‐Zepeda, L. A.
Publicado no Int J Cancer (2017)

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

Por Rustad, E H, Dai, H Y, Hov, H, Coward, E, Beisvag, V, Myklebost, O, Hovig, E, Nakken, S, Vodák, D, Meza-Zepeda, L A, Sandvik, A K, Wader, K F, Misund, K, Sundan, A, Aarset, H, Waage, A
Publicado no Blood Cancer J (2015)